FDA asks drug firm to stop selling opioid analgesic Opana ER
The U.S. Food and Drug Administration (FDA) has requested that Endo Pharmaceuticals stop selling the reformulated version of its opioid analgesic Opana ER due to the risk for abuse. Opana ER was first approved in 2006, and Endo Pharmaceuticals changed the original formula in 2012 to make the drug harder to abuse by snorting or injecting. However, after reviewing more information about the risks of the new Opana ER formula,






